Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | PTPRA | P18433 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | GRM8 | O00222 | 1/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.51 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817775 | 1.00 | CYP1A2 (0.61) | CYP1A2PTPRACYP2C19GRM8GRM4 | |
| SCHEMBL30959758 | 1.00 | CYP1A2 (0.61) | CYP1A2PTPRACYP2C19GRM8GRM4 | |
| SCHEMBL385176 | 0.85 | GRIA2 (0.51) | CYP1A2PTPRACYP2C19GRIA2TDP1 | |
| SCHEMBL385177 | 0.85 | GRIA2 (0.51) | CYP1A2PTPRACYP2C19GRIA2TDP1 | |
| SCHEMBL9755057 | 0.85 | CYP1A2 (0.57) | CYP1A2PTPRAGRM8GRM4KMO | |
| SCHEMBL16671961 | 0.84 | PTPRA (0.60) | CYP1A2PTPRACYP2C19GRM8GRM4 | |
| SCHEMBL12226104 | 0.84 | PTPRA (0.60) | CYP1A2PTPRACYP2C19GRIA2KMO | |
| SCHEMBL2127356 | 0.84 | GRIA2 (0.50) | CYP1A2PTPRACYP2C19GRIA2TDP1 | |
| SCHEMBL7257400 | 0.84 | PTPRA (0.60) | CYP1A2PTPRACYP2C19GRM8GRM4 | |
| SCHEMBL17002633 | 0.84 | GRIA2 (0.50) | CYP1A2PTPRACYP2C19GRIA2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6194143-B1 | MEASUREMENT ACTIVITY BY MONITORING SUBSTRATE CLEAVAGE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-02-27 | — | — | US | claimed |
| EP-0948640-A2 | IMPROVED SUBSTRATES FOR HUMAN CYTOMEGALOVIRUS PROTEASE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-10-13 | — | — | EP | claimed |
| WO-1998029562-A2 | IMPROVED SUBSTRATES FOR HUMAN CYTOMEGALOVIRUS PROTEASE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-07-09 | — | — | WO | claimed |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | disclosed |
| US-20240398842-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2024-12-05 | — | — | US | disclosed |
| US-12121505-B2 | Fap-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-10-22 | — | — | US | disclosed |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-08-06 | — | — | US | disclosed |
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-1948243-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | Aeris Therapeutics, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1945797-A1 | HEPATITIS C VIRUS NS2/3 ACTIVITY ASSAY | Boehringer Ingelheim International GmbH (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070265255-A1 | SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS | GEORGETOWN UNIVERSITY | 2007-11-15 | — | — | US | disclosed |
| US-20070212754-A1 | Hepatitis C Virus NS2/3 Activity Assay | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007048254-A1 | HEPATITIS C VIRUS NS2/3 ACTIVITY ASSAY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| US-6194143-B1 | MEASUREMENT ACTIVITY BY MONITORING SUBSTRATE CLEAVAGE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121505-B2 | Fap-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | CYP1A2 2416/4885PTPRA 217/4885CYP2C19 3287/4885 |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | CYP1A2 2416/4885PTPRA 217/4885CYP2C19 3287/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | CYP1A2 2416/4885PTPRA 217/4885CYP2C19 3287/4885 |
| US-20070265255-A1 | SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS | ADH5, ADH1C, ADH1A | CYP1A2 15/4885PTPRA 3895/4885CYP2C19 239/4885 |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | CYP1A2 2416/4885PTPRA 217/4885CYP2C19 3287/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | CYP1A2 1625/4885PTPRA 114/4885CYP2C19 3010/4885 |
| US-20240398842-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | CYP1A2 1575/4885PTPRA 116/4885CYP2C19 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.